The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: The GFM experience

摘要

The International Prognostic Scoring System (IPSS), which is based on cytogenetics, BM blast percentage, and number of cytopenias, has played a major role in prognosis assessment in myelodysplastic syndrome (MDS) since its publication in 1997. The recently published revised IPSS (IPSS-R), which uses the same parameters as the original except for using 5 rather than 3 cytogenetic subgroups, new cutoff values for cytopenias and BM blast percentages, and different weighing of parameters, refines the original IPSS prognostic value. However, like the original IPSS, the IPSS-R was also established in patients who had received no disease-modifying drugs. We previously reported that peripheral blast percentages, performance status, RBC transfusion requirement, and original IPSS cytogenetic risk independently predicted overall survival (OS) in 282 IPSS high-risk and intermediate 2-risk MDS patients treated with azacitidine (AZA) in a compassionate patient-named program.